Preparing for RSV Immunisation and Surveillance in Europe


IMI Funding: 3.744.375 €
EFPIA in kind: 3.280.012 €
Total Cost: 7.024.387 €


  • UEDIN The University of Edinburgh (United Kingdom)
  • UMCU Universitair Medisch Centrum Utrecht (Netherlands)
  • UA Universiteit Antwerpen (Belgium)
  • Imperial Imperial College of Science, Technology and Medicine (United Kingdom)
  • UOXF The Chancellor, Masters and Scholars of the University of Oxford (United Kingdom)
  • THL Terveyden Ja Hyvinvoinnin Laitos (Finland)
  • RIVM Rijksinstituut voor Volksgezondheid en Milieu (Netherlands)
  • NIVEL Stichting Nedelands Instituut voor Onderzoek van de Gezondheidzorg (Netherlands)
  • TUCH Varsinais-Suomen Sairaanhoitopiirin Kuntayhtymä (Finland)
  • TEAMIT TEAM IT Research, S.L. (Spain)
  • ReSViNET Stichting Resvinet (Netherlands)
  • SSI Statens Serum Institut (Denmark)
  • SERGAS Servizo Galego de Saúde (Spain)
  • PENTA Fondazione PENTA – For the treatment and care of children with HIV and related diseases – ONLUS (Italy)
  • FISABIO Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Spain)
  • MLU Martin-Luther-Universitaet Halle-Wittenberg (Germany)
  • SP Sanofi Pasteur, S.A. (France)
  • GSK GlaxoSmithKline Biologicals, S.A. (Belgium)
  • JANSSEN Janssen Pharmaceuticals, N.V (Belgium)
  • Novavax Novavax, Inc. (United States)
  • Pfizer Pfizer Limited (United Kingdom)
  • AZ AstraZeneca AB (Sweden)


  • Harish Nair, Project scientific co-coordinator, Professor of Paediatric Infectious Diseases and Global Health at University of Edinburgh (UEDIN)
  • & Louis Bont, Project scientific co-coordinator, Professor of Paediatric Infectious Diseases and Immunology at University Medical Centre Utrecht (UMCU).

Project leader: Charlotte Vernhes, Project leader Translational Lead Scientist at Sanofi Pasteur

Through PROMISE, TEAMIT contributes to paving the way to RSV prevention, treatment and immunisation. PROMISE will continue advancing scientific knowledge on Respiratory Syncytial Virus (RSV) to better inform public health strategies and to support the development and monitoring of novel immunisation and therapeutics against this potentially deadly virus in the paediatric and elderly populations. PROMISE builds on RESCEU’s results, another Innovative Medicines Initiative project focusing on RSV.